FDA Peptide Vote Could Ignite Telehealth's Next Billion-Dollar Market

The U.S. Food and Drug Administration's (FDA) compounding advisory committee is scheduled to review seven peptides on July 23 and 24, a decision that could pave the way for a new multibillion-dollar market within the telehealth sector. These peptides, which are short protein fragments used for purposes such as accelerating recovery, boosting energy, and slowing aging, are gaining significant traction. The review will focus on peptides like BPC-157 and TB-500, which are currently popular among biohackers and wellness enthusiasts.

If the FDA approves these peptides for legal mixing by specialty pharmacies, it could replicate the success seen with compounding pharmacies that previously created a "shadow industry" around "cheap Ozempic." Telehealth companies, particularly those that experienced growth from offering compounded versions of weight-loss drugs like Ozempic and Wegovy, are poised to capitalize on this development. Hims & Hers, a prominent telehealth provider, is actively preparing to expand its peptide offerings. The company's chief medical officer, Dr. Anant Vinjamoori, is scheduled to testify at the FDA hearing, and Hims & Hers has previously stated its belief in the potential of certain peptide therapies to improve Americans' health.

The potential market impact is significant, as evidenced by the previous success of compounded drugs. Hims & Hers, for instance, saw its stock fluctuate as the FDA addressed supply shortages and considered excluding compounded drugs from certain lists. This experience has prompted the company to diversify its services, with peptides now positioned as a key growth area. Telehealth infrastructure companies are also anticipating a surge in activity. Michelle Davey, CEO of Wheel, predicts that major telehealth players will quickly enter the peptide market once regulatory approval is granted, sourcing from reputable pharmacies. Research from Needham suggests a substantial addressable market for these wellness peptides.